To repeal sections 195.017 and 263.250, RSMo, and to enact in lieu thereof nine new sections
relating to the use of marijuana for medicinal purposes, with penalty provisions and a
referendum clause.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Sections 195.017 and 263.250, RSMo, are repealed and nine new sections
enacted in lieu thereof, to be known as sections 195.017, 195.580, 195.583, 195.586, 195.589,
195.592, 195.595, 195.598, and 263.250, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in
Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted
safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these
isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

(g) Alpha-methylfentanyl;

(h) Alpha-methylthiofentanyl;

(i) Benzethidine;

(j) Betacetylmethadol;

(k) Beta-hydroxyfentanyl;

(l) Beta-hydroxy-3-methylfentanyl;

(m) Betameprodine;

(n) Betamethadol;

(o) Betaprodine;

(p) Clonitazene;

(q) Dextromoramide;

(r) Diampromide;

(s) Diethylthiambutene;

(t) Difenoxin;

(u) Dimenoxadol;

(v) Dimepheptanol;

(w) Dimethylthiambutene;

(x) Dioxaphetyl butyrate;

(y) Dipipanone;

(z) Ethylmethylthiambutene;

(aa) Etonitazene;

(bb) Etoxeridine;

(cc) Furethidine;

(dd) Hydroxypethidine;

(ee) Ketobemidone;

(ff) Levomoramide;

(gg) Levophenacylmorphan;

(hh) 3-Methylfentanyl;

(ii) 3-Methylthiofentanyl;

(jj) Morpheridine;

(kk) MPPP;

(ll) Noracymethadol;

(mm) Norlevorphanol;

(nn) Normethadone;

(oo) Norpipanone;

(pp) Para-fluorofentanyl;

(qq) PEPAP;

(rr) Phenadoxone;

(ss) Phenampromide;

(tt) Phenomorphan;

(uu) Phenoperidine;

(vv) Piritramide;

(ww) Proheptazine;

(xx) Properidine;

(yy) Propiram;

(zz) Racemoramide;

(aaa) Thiofentanyl;

(bbb) Tilidine;

(ccc) Trimeperidine;

(3) Any of the following opium derivatives, their salts, isomers and salts of isomers
unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
is possible within the specific chemical designation:

(a) Acetorphine;

(b) Acetyldihydrocodeine;

(c) Benzylmorphine;

(d) Codeine methylbromide;

(e) Codeine-N-Oxide;

(f) Cyprenorphine;

(g) Desomorphine;

(h) Dihydromorphine;

(i) Drotebanol;

(j) Etorphine (except hydrochloride salt);

(k) Heroin;

(l) Hydromorphinol;

(m) Methyldesorphine;

(n) Methyldihydromorphine;

(o) Morphine methylbromide;

(p) Morphine methylsulfonate;

(q) Morphine-N-Oxide;

(r) Myrophine;

(s) Nicocodeine;

(t) Nicomorphine;

(u) Normorphine;

(v) Pholcodine;

(w) Thebacon;

(4) Any material, compound, mixture or preparation which contains any quantity of the
following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
the specific chemical designation:

(a) 4-bromo-2, 5-dimethoxyamphetamine;

(b) 4-bromo-2, 5-dimethoxyphenethylamine;

(c) 2,5-dimethoxyamphetamine;

(d) 2,5-dimethoxy-4-ethylamphetamine;

(e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;

(f) 4-methoxyamphetamine;

(g) 5-methoxy-3,4-methylenedioxyamphetamine;

(h) 4-methyl-2, 5-dimethoxyamphetamine;

(i) 3,4-methylenedioxyamphetamine;

(j) 3,4-methylenedioxymethamphetamine;

(k) 3,4-methylenedioxy-N-ethylamphetamine;

(l) N-hydroxy-3, 4-methylenedioxyamphetamine;

(m) 3,4,5-trimethoxyamphetamine;

(n) Alpha-ethyltryptamine;

(o) Alpha-methyltryptamine;

(p) Bufotenine;

(q) Diethyltryptamine;

(r) Dimethyltryptamine;

(s) 5-methoxy-N,N-diisopropyltryptamine;

(t) Ibogaine;

(u) Lysergic acid diethylamide;

(v) [Marijuana or marihuana;

(w)] Mescaline;

[(x)](w) Parahexyl;

[(y)](x) Peyote, to include all parts of the plant presently classified botanically as
Lophophora Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any
part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of
the plant, its seed or extracts;

[(z)](y) N-ethyl-3-piperidyl benzilate;

[(aa)](z) N-methyl-3-piperidyl benzilate;

[(bb)](aa) Psilocybin;

[(cc)](bb) Psilocyn;

[(dd)](cc) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
(cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
isomers with similar chemical structure and pharmacological activity to those substances
contained in the plant, such as the following:

a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;

b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;

c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;

d. Any compounds of these structures, regardless of numerical designation of atomic
positions covered;

[(ee)](dd) Ethylamine analog of phencyclidine;

[(ff)](ee) Pyrrolidine analog of phencyclidine;

[(gg)](ff) Thiophene analog of phencyclidine;

[(hh)](gg) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

[(ii)](hh) Salvia divinorum;

[(jj)](ii) Salvinorin A;

(5) Any material, compound, mixture or preparation containing any quantity of the
following substances having a depressant effect on the central nervous system, including their
salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
isomers is possible within the specific chemical designation:

(a) Gamma-hydroxybutyric acid;

(b) Mecloqualone;

(c) Methaqualone;

(6) Any material, compound, mixture or preparation containing any quantity of the
following substances having a stimulant effect on the central nervous system, including their
salts, isomers and salts of isomers:

(7) A temporary listing of substances subject to emergency scheduling under federal law
shall include any material, compound, mixture or preparation which contains any quantity of the
following substances:

(8) Khat, to include all parts of the plant presently classified botanically as catha edulis,
whether growing or not; the seeds thereof; any extract from any part of such plant; and every
compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

3. The department of health and senior services shall place a substance in Schedule II
if it finds that:

(1) The substance has high potential for abuse;

(2) The substance has currently accepted medical use in treatment in the United States,
or currently accepted medical use with severe restrictions; and

(3) The abuse of the substance may lead to severe psychic or physical dependence.

4. The controlled substances listed in this subsection are included in Schedule II:

(1) Any of the following substances whether produced directly or indirectly by extraction
from substances of vegetable origin, or independently by means of chemical synthesis, or by
combination of extraction and chemical synthesis:

(a) Opium and opiate and any salt, compound, derivative or preparation of opium or
opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine,
nalmefene, naloxone and naltrexone, and their respective salts but including the following:

a. Raw opium;

b. Opium extracts;

c. Opium fluid;

d. Powdered opium;

e. Granulated opium;

f. Tincture of opium;

g. Codeine;

h. Ethylmorphine;

i. Etorphine hydrochloride;

j. Hydrocodone;

k. Hydromorphone;

l. Metopon;

m. Morphine;

n. Oxycodone;

o. Oxymorphone;

p. Thebaine;

(b) Any salt, compound, derivative, or preparation thereof which is chemically
equivalent or identical with any of the substances referred to in this subdivision, but not
including the isoquinoline alkaloids of opium;

(c) Opium poppy and poppy straw;

(d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
with any of these substances, but not including decocainized coca leaves or extractions which
do not contain cocaine or ecgonine;

(e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
or powder form which contains the phenanthrene alkaloids of the opium poppy);

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
the specific chemical designation, dextrorphan and levopropoxyphene excepted:

(3) Any material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system:

(a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;

(b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;

(c) Methamphetamine, its salts, isomers, and salts of its isomers;

(d) Phenmetrazine and its salts;

(e) Methylphenidate;

(4) Any material, compound, mixture, or preparation which contains any quantity of the
following substances having a depressant effect on the central nervous system, including its salts,
isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
is possible within the specific chemical designation:

(a) Amobarbital;

(b) Glutethimide;

(c) Pentobarbital;

(d) Phencyclidine;

(e) Secobarbital;

(5) Any material or compound which contains any quantity of nabilone;

(6) Any material, compound, mixture, or preparation which contains any quantity of the
following substances:

(7) Any material, compound, mixture, or preparation which contains any quantity
of the following substances having a depressant effect on the central nervous system,
including its salts, isomers, and salts of isomers whenever the existence of those salts,
isomers, and salts of isomers is possible within the specific chemical designation:
Marijuana.

5. The department of health and senior services shall place a substance in Schedule III
if it finds that:

(1) The substance has a potential for abuse less than the substances listed in Schedules
I and II;

(2) The substance has currently accepted medical use in treatment in the United States;
and

(3) Abuse of the substance may lead to moderate or low physical dependence or high
psychological dependence.

6. The controlled substances listed in this subsection are included in Schedule III:

(1) Any material, compound, mixture, or preparation which contains any quantity of the
following substances having a potential for abuse associated with a stimulant effect on the
central nervous system:

(a) Benzphetamine;

(b) Chlorphentermine;

(c) Clortermine;

(d) Phendimetrazine;

(2) Any material, compound, mixture or preparation which contains any quantity or salt
of the following substances or salts having a depressant effect on the central nervous system:

(a) Any material, compound, mixture or preparation which contains any quantity or salt
of the following substances combined with one or more active medicinal ingredients:

a. Amobarbital;

b. Secobarbital;

c. Pentobarbital;

(b) Any suppository dosage form containing any quantity or salt of the following:

a. Amobarbital;

b. Secobarbital;

c. Pentobarbital;

(c) Any substance which contains any quantity of a derivative of barbituric acid or its
salt;

(d) Chlorhexadol;

(e) Embutramide;

(f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
a drug product for which an application has been approved under Section 505 of the federal
Food, Drug, and Cosmetic Act;

(g) Ketamine, its salts, isomers, and salts of isomers;

(h) Lysergic acid;

(i) Lysergic acid amide;

(j) Methyprylon;

(k) Sulfondiethylmethane;

(l) Sulfonethylmethane;

(m) Sulfonmethane;

(n) Tiletamine and zolazepam or any salt thereof;

(3) Nalorphine;

(4) Any material, compound, mixture, or preparation containing limited quantities of any
of the following narcotic drugs or their salts:

(a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
of opium;

(b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts;

(c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
isoquinoline alkaloid of opium;

(d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
ingredients in recognized therapeutic amounts;

(e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
recognized therapeutic amounts;

(f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts;

(g) Not more than five hundred milligrams of opium per one hundred milliliters or per
one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
active nonnarcotic ingredients in recognized therapeutic amounts;

(h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
amounts;

(5) Any material, compound, mixture, or preparation containing any of the following
narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

(6) Anabolic steroids. Any drug or hormonal substance, chemically and
pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is
expressly intended for administration through implants to cattle or other nonhuman species and
which has been approved by the Secretary of Health and Human Services for that administration.
If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
meaning of this paragraph. Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture or preparation containing any quantity of the following substances,
including its salts, esters and ethers:

(hhh) Any salt, ester, or ether of a drug or substance described or listed in this
subdivision, except an anabolic steroid which is expressly intended for administration through
implants to cattle or other nonhuman species and which has been approved by the Secretary of
Health and Human Services for that administration;

(7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
United States Food and Drug Administration approved drug product;

(8) The department of health and senior services may except by rule any compound,
mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
(1) and (2) of this subsection from the application of all or any part of sections 195.010 to
195.320 if the compound, mixture, or preparation contains one or more active medicinal
ingredients not having a stimulant or depressant effect on the central nervous system, and if the
admixtures are included therein in combinations, quantity, proportion, or concentration that
vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
the central nervous system.

7. The department of health and senior services shall place a substance in Schedule IV
if it finds that:

(1) The substance has a low potential for abuse relative to substances in Schedule III;

(2) The substance has currently accepted medical use in treatment in the United States;
and

(3) Abuse of the substance may lead to limited physical dependence or psychological
dependence relative to the substances in Schedule III.

8. The controlled substances listed in this subsection are included in Schedule IV:

(1) Any material, compound, mixture, or preparation containing any of the following
narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
as set forth below:

(a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
of atropine sulfate per dosage unit;

(c) Any of the following limited quantities of narcotic drugs or their salts, which shall
include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
upon the compound, mixture or preparation valuable medicinal qualities other than those
possessed by the narcotic drug alone:

a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
one hundred grams;

b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
or per one hundred grams;

c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
or per one hundred grams;

(2) Any material, compound, mixture or preparation containing any quantity of the
following substances, including their salts, isomers, and salts of isomers whenever the existence
of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

(a) Alprazolam;

(b) Barbital;

(c) Bromazepam;

(d) Camazepam;

(e) Chloral betaine;

(f) Chloral hydrate;

(g) Chlordiazepoxide;

(h) Clobazam;

(i) Clonazepam;

(j) Clorazepate;

(k) Clotiazepam;

(l) Cloxazolam;

(m) Delorazepam;

(n) Diazepam;

(o) Dichloralphenazone;

(p) Estazolam;

(q) Ethchlorvynol;

(r) Ethinamate;

(s) Ethyl loflazepate;

(t) Fludiazepam;

(u) Flunitrazepam;

(v) Flurazepam;

(w) Halazepam;

(x) Haloxazolam;

(y) Ketazolam;

(z) Loprazolam;

(aa) Lorazepam;

(bb) Lormetazepam;

(cc) Mebutamate;

(dd) Medazepam;

(ee) Meprobamate;

(ff) Methohexital;

(gg) Methylphenobarbital (mephobarbital);

(hh) Midazolam;

(ii) Nimetazepam;

(jj) Nitrazepam;

(kk) Nordiazepam;

(ll) Oxazepam;

(mm) Oxazolam;

(nn) Paraldehyde;

(oo) Petrichloral;

(pp) Phenobarbital;

(qq) Pinazepam;

(rr) Prazepam;

(ss) Quazepam;

(tt) Temazepam;

(uu) Tetrazepam;

(vv) Triazolam;

(ww) Zaleplon;

(xx) Zolpidem;

(yy) Zopiclone;

(3) Any material, compound, mixture, or preparation which contains any quantity of the
following substance including its salts, isomers and salts of isomers whenever the existence of
such salts, isomers and salts of isomers is possible: fenfluramine;

(4) Any material, compound, mixture or preparation containing any quantity of the
following substances having a stimulant effect on the central nervous system, including their
salts, isomers and salts of isomers:

(5) Any material, compound, mixture or preparation containing any quantity of the
following substance, including its salts:

(a) butorphanol;

(b) pentazocine;

(6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
is the only active medicinal ingredient;

(7) The department of health and senior services may except by rule any compound,
mixture, or preparation containing any depressant substance listed in subdivision (1) of this
subsection from the application of all or any part of sections 195.010 to 195.320 if the
compound, mixture, or preparation contains one or more active medicinal ingredients not having
a depressant effect on the central nervous system, and if the admixtures are included therein in
combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
substances which have a depressant effect on the central nervous system.

9. The department of health and senior services shall place a substance in Schedule V
if it finds that:

(1) The substance has low potential for abuse relative to the controlled substances listed
in Schedule IV;

(2) The substance has currently accepted medical use in treatment in the United States;
and

(3) The substance has limited physical dependence or psychological dependence liability
relative to the controlled substances listed in Schedule IV.

10. The controlled substances listed in this subsection are included in Schedule V:

(1) Any compound, mixture or preparation containing any of the following narcotic
drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
forth below, which also contains one or more nonnarcotic active medicinal ingredients in
sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
qualities other than those possessed by the narcotic drug alone:

(a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
twenty-five micrograms of atropine sulfate per dosage unit;

(b) Not more than one hundred milligrams of opium per one hundred milliliters or per
one hundred grams;

(c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
micrograms of atropine sulfate per dosage unit;

(2) Any material, compound, mixture or preparation which contains any quantity of the
following substance having a stimulant effect on the central nervous system including its salts,
isomers and salts of isomers: pyrovalerone;

(3) Any compound, mixture, or preparation containing any detectable quantity of
pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
isomers, or salts of optical isomers;

(4) Unless specifically exempted or excluded or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the following
substances having a depressant effect on the central nervous system, including its salts:
pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

11. If any compound, mixture, or preparation as specified in subdivision (3) of
subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
prescription:

(1) All packages of any compound, mixture, or preparation containing any detectable
quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
registered pharmacy technician; and

(2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
shall be at least eighteen years of age; and

(3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,
or preparation to furnish suitable photo identification that is issued by a state or the federal
government or a document that, with respect to identification, is considered acceptable and
showing the date of birth of the person;

(4) The seller shall deliver the product directly into the custody of the purchaser.

12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
implement and maintain an electronic log of each transaction. Such log shall include the
following information:

(1) The name, address, and signature of the purchaser;

(2) The amount of the compound, mixture, or preparation purchased;

(3) The date and time of each purchase; and

(4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
technician who dispensed the compound, mixture, or preparation to the purchaser.

13. Each pharmacy shall submit information regarding sales of any compound, mixture,
or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
transmission methods and frequency established by the department by regulation;

14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
greater than those specified in this chapter.

15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
where the public is not permitted.

16. Any person who knowingly or recklessly violates the provisions of subsections 11
to 15 of this section is guilty of a class A misdemeanor.

17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

18. The manufacturer of a drug product or another interested party may apply with the
department of health and senior services for an exemption from this section. The department of
health and senior services may grant an exemption by rule from this section if the department
finds the drug product is not used in the illegal manufacture of methamphetamine or other
controlled or dangerous substances. The department of health and senior services shall rely on
reports from law enforcement and law enforcement evidentiary laboratories in determining if the
proposed product can be used to manufacture illicit controlled substances.

19. The department of health and senior services shall revise and republish the schedules
annually.

20. The department of health and senior services shall promulgate rules under chapter
536, RSMo, regarding the security and storage of Schedule V controlled substances, as described
in subdivision (3) of subsection 10 of this section, for distributors as registered by the department
of health and senior services.

21. Logs of transactions required to be kept and maintained by this section and section
195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
the person whose transactions are recorded in the logs.

195.580. As used in sections 195.580 to 195.589, the following terms mean:

(1) "Adequate supply", an amount of marijuana collectively possessed between the
qualifying patient and the qualifying patient's primary caregivers that is not more than is
reasonably necessary to ensure the uninterrupted availability of marijuana for the purpose
of alleviating the symptoms or effects of a qualifying patient's debilitating medical
condition; provided that an "adequate supply" shall not exceed three mature marijuana
plants, four immature marijuana plants, and one ounce of usable marijuana per each
mature plant;

(b) A chronic or debilitating disease or medical condition or its treatment that
produces one or more of the following: cachexia or wasting syndrome; severe pain; severe
nausea; anorexia; seizures, including those characteristic of epilepsy; or severe and
persistent muscle spasms, including those characteristic of multiple sclerosis (MS), Lou
Gehrig's disease (ALS), or Crohn's disease; or

(c) Any other serious medical condition or its treatment approved by a licensed
physician;

(4) "Department", the department of health and senior services;

(5) "Immature marijuana plants", any cannabis plant, devoid of flowers or buds,
from seedling to the beginning states of flowering, signifying the first state of processing
for consumption as medicine;

(6) "Mature marijuana plants", any cannabis plant bearing flowers or buds,
signifying the second stage of processing for consumption as medicine;

(7) "Medical marijuana", cannabis sativa grown within a controlled environment
for the purposes of being used as a medicine;

(8) "Medical use", the acquisition, possession, cultivation, use, transfer, or
transportation of marijuana or paraphernalia relating to the administration of marijuana
to alleviate the symptoms or effects of a qualifying patient's debilitating medical condition.
For the purposes of "medical use", the term "transfer" is limited to the transfer of
marijuana and paraphernalia between primary caregivers and qualifying patients;

(9) "Physician", a person who is licensed under section 334.021 and is licensed with
authority to prescribe drugs under section 334.021;

(10) "Primary caregiver", a person who is at least eighteen years of age and who
has agreed to undertake responsibility for managing the well-being of a person with
respect to the medical use of marijuana;

(11) "Qualifying patient", a person who has been diagnosed by a physician as
having a debilitating medical condition;

(12) "Usable marijuana", the dried leaves and flowers of marijuana, and any
mixture or preparation thereof, that are appropriate for the medical use of marijuana, and
does not include the seeds, stalks, and roots of the plant;

(13) "Written certification", the qualifying patient's medical records or a statement
signed by a physician stating that in the physician's professional opinion, after having
completed a full assessment of the qualifying patient's medical history and current medical
condition made in the course of a bona fide physician-patient relationship, the qualifying
patient has a debilitating medical condition and the potential benefits of the medical use
of marijuana would likely outweigh the health risks for the qualifying patient.

195.583. 1. A qualifying patient who has in his or her possession written
certification shall not be subject to arrest, prosecution, or penalty in any manner for the
medical use of marijuana, provided the quantity of marijuana does not exceed an adequate
supply.

2. Subsection 1 of this section shall not apply to a qualifying patient under the age
of eighteen, unless:

(1) The qualifying patient's physician has explained the potential risks and benefits
of the medical use of marijuana to the qualifying patient and to a parent, guardian, or
person having legal custody of the qualifying patient; and

(2) A parent, guardian, or person having legal custody consents in writing to:

(a) Allow the qualifying patient's medical use of marijuana;

(b) Serve as the qualifying patient's primary caregiver; and

(c) Control the acquisition of the marijuana, the dosage, and the frequency of the
medical use of marijuana by the qualifying patient.

3. When the acquisition, possession, cultivation, transportation, or administration
of marijuana by a qualifying patient is not practicable, the legal protections established by
sections 195.580 to 195.598 for a qualifying patient shall extend to the qualifying patient's
primary caregivers, provided that the primary caregivers' actions are necessary for the
qualifying patient's medical use of marijuana.

4. A physician shall not be subject to arrest or prosecution, penalized in any
manner, or denied any right or privilege for providing written certification for the medical
use of marijuana to qualifying patients.

5. Any property interest that is possessed, owned, or used in connection with the
medical use of marijuana, or acts incidental to such use shall not be harmed, neglected,
injured, or destroyed while in the possession of state or local law enforcement officials.

6. Marijuana plants, equipment for their cultivation, as well as legal amounts of
medical marijuana shall not be seized from the possession of a medical patient if the
medical patient presents identification as a medical marijuana patient. Any such property
interest shall not be forfeited under any provision of state or local law providing for the
forfeiture of property other than as a sentence imposed after conviction of a criminal
offense or entry of a plea of guilty to a criminal offense. Marijuana, paraphernalia, or
other property seized from a qualifying patient or primary caregivers in connection with
the claimed medical use of marijuana shall be returned immediately upon the
determination by a court or prosecutor that the qualifying patient or primary caregivers
are entitled to the protections of 195.550 to 195.568, as may be evidenced by a decision not
to prosecute, the dismissal of charges, or an acquittal.

7. No person shall be subject to arrest or prosecution for "constructive possession",
"conspiracy", or any other offense for simply being in the presence or vicinity of the
medical use of marijuana as permitted under sections 195.580 to 195.583.

8. Any medical marijuana patient shall be afforded all the same rights under the
law as any other pharmaceutically medicated individual, as it pertains to:

(1) Routine traffic stops as well as any interaction with law enforcement that does
not involve an illegal act;

(2) Any interaction with a person's employer that pertains solely to legal medical
marijuana use; or

(3) Exoneration from drug testing when such test pertains to marijuana and its
metabolites whether by an employer or a member of law enforcement.

9. A patient or caregiver who has not received a registry identification card may
present evidence supporting his or her need for medical marijuana for treatment of a
serious medical condition. Such evidence may constitute a defense to a charge of
marijuana possession or cultivation and shall be admissible in the courts of the state of
Missouri if such evidence otherwise properly qualifies as admissible under the rules of
evidence.

195.586. 1. The authorization for the medical use of marijuana in sections 195.580
to 195.598 shall not apply to:

(1) The medical use of marijuana that compromises the health or well-being of
another person, such as:

(a) In a school bus, public bus, or other public vehicle;

(b) In the areas of one's employment not designated for medical marijuana use;

(c) On any school grounds other than areas designated for medical marijuana use;

(d) In any correctional facility other than areas designated for medical marijuana
use; or

(e) At any public park, public beach, public recreation center, or youth center other
than areas designated for medical marijuana use; and

(2) The use of marijuana by a qualifying patient, primary caregiver, or any other
person for purposes other than medical use permitted by sections 195.580 to 195.598.

2. Notwithstanding any law to the contrary, fraudulent representation to a law
enforcement official of any fact or circumstance relating to the medical use of marijuana
to avoid arrest or prosecution shall be a petty misdemeanor and subject to a fine of five
hundred dollars. Such penalty shall be in addition to any other penalties that may apply
for the nonmedical use of marijuana.

195.589. A person and a person's primary caregivers may assert the medical use
of marijuana as a defense to any prosecution involving marijuana, and such defense shall
be presumed valid where the evidence shows that:

(1) The person's medical records indicate or a physician has stated that, in the
physician's professional opinion after having completed a full assessment of the person's
medical history and current medical condition made in the course of a bona fide physician-patient relationship, the potential benefits of the medical use of marijuana would likely
outweigh the health risks for the person; and

(2) The person and the person's primary caregivers were collectively in possession
of a quantity of marijuana that was not more than was reasonably necessary to ensure the
uninterrupted availability of marijuana for the purpose of alleviating the symptoms or
effects of the person's medical condition.

195.592. 1. "Registry identification card" means a document issued by the
department that identifies a person as a qualifying patient or primary caregiver.

2. Not later than ninety days after the effective date of sections 195.580 to 195.598,
the department shall promulgate rules governing the manner in which it will consider
applications for registry identification cards, and for renewing registry identification
cards, for qualifying patients and primary caregivers.

3. The department shall issue registry identification cards to qualifying patients,
and to qualifying patients' primary caregivers, if any, who submit the following, in
accordance with the department's rules:

(1) Written certification that the person is a qualifying patient;

(2) Registration fee, not to exceed one hundred dollars per qualifying patient;

(3) Name, address, and date of birth of the qualifying patient;

(4) Name, address, and telephone number of the qualifying patient's physician; and

(5) Name, address, and date of birth of the qualifying patient's primary caregivers,
if the qualifying patient has designated any primary caregivers at the time of application.

4. The department shall verify the information contained in an application
submitted under this section, and shall approve or deny an application within thirty days
of receipt of the application. The department may deny an application only if the applicant
did not provide the information required under this section, or if the department
determines that the information provided was falsified. Any person whose application has
been denied shall not reapply for six months from the date of the denial, unless so
authorized by the department or a court of competent jurisdiction.

5. The department shall issue registry identification cards within five days of
approving an application, which shall expire one year after the date of issuance. Registry
identification cards shall contain:

(1) The name, address, and date of birth of the qualifying patient and primary
caregivers, if any;

(2) The date of issuance and expiration date of the registry identification card; and

(3) Other information that the department may specify in its rules.

6. A person who possesses a registry identification card shall notify the department
of any change in the person's name, address, qualifying patient's physician, qualifying
patient's primary caregiver, or change in status of the qualifying patient's debilitating
medical condition within ten days of such change, or the registry identification card shall
be deemed null and void.

7. Possession of or application for a registry identification card alone shall not
constitute probable cause to search the person or property of the person possessing or
applying for the card or otherwise subject the person or property of the person possessing
the card to inspection by any governmental agency.

8. The department shall maintain a confidential list of the persons to whom the
department has issued registry identification cards. Individual names on the list shall be
confidential and not subject to disclosure, except to:

(1) Authorized employees of the department as necessary to perform official duties
of the department; or

(2) Authorized employees of state or local law enforcement agencies, only for the
purpose of verifying that a person who is engaged in the suspected or alleged medical use
of marijuana is lawfully in possession of a registry identification card.

195.595. 1. A "registered organization" means a nonprofit corporation registered
with the state under chapter 355, RSMo, and organized for the purpose of lawfully selling,
administering, delivering, dispensing, distributing, cultivating, or possessing marijuana,
cultivation equipment, related supplies and educational materials, or marijuana seeds for
medical use.

2. Prior to selling, administering, delivering, dispensing, distributing, cultivating,
or possessing marijuana for medical use, a registered organization shall file a registration
statement with the department and thereafter shall file an annual registration statement
with the department in accordance with department rules which shall provide for the form
and content of the registration statement.

3. Not later than ninety days after the effective date of sections 195.580 to 195.598,
the department shall promulgate rules that include procedures for the oversight of
registered organizations, specifications for the membership of the staff and the boards of
directors of registered organizations, appropriate protections for people associated with
registered organizations, a registration system for qualifying patients and primary
caregivers who use the services of registered organizations, recordkeeping and reporting
requirements for registered organizations, the potential transference or sale of seized
cultivation equipment and related supplies from law enforcement agencies to registered
organizations, and procedures for suspending or terminating the registration of registered
organizations.

4. It shall be lawful to sell, administer, deliver, dispense, distribute, cultivate, or
possess marijuana where it is:

(1) By a registered organization to a qualifying patient or primary caregiver; or

(2) By any federal, state, or local law enforcement agency to a registered
organization.

5. A registered organization shall not:

(1) Obtain marijuana from outside the state in violation of federal law;

(2) Employ or utilize the services of any person who has a felony conviction
involving a controlled substance offense; or

(3) Sell, administer, deliver, dispense, or distribute marijuana to qualifying patients
or primary caregivers without first verifying the validity of the qualifying patient's written
certification by:

(a) Contacting the office of the qualifying patient's physician; and

(b) Contacting the appropriate state medical board or association to determine that
the physician is licensed to practice medicine under chapter 334.

195.598. Any rule or portion of a rule, as that term is defined in section 536.010,
that is created under the authority delegated in sections 195.580 to 195.598 shall become
effective only if it complies with and is subject to all of the provisions of chapter 536 and,
if applicable, section 536.028. Sections 195.580 to 195.598 and chapter 536 are
nonseverable and if any of the powers vested with the general assembly pursuant to
chapter 536 to review, to delay the effective date, or to disapprove and annul a rule are
subsequently held unconstitutional, then the grant of rulemaking authority and any rule
proposed or adopted after August 28, 2010, shall be invalid and void.

263.250. 1. Except as provided in sections 195.550 to 195.568, the plant "marijuana",
botanically known as cannabis sativa, is hereby declared to be a noxious weed and all owners
and occupiers of land shall destroy all such plants growing upon their land. Any person who
knowingly allows such plants to grow on his land or refuses to destroy such plants after being
notified to do so shall allow any sheriff or such other persons as designated by the county
commission to enter upon any land in this state and destroy such plants.

2. Entry to such lands shall not be made, by any sheriff or other designated person to
destroy such plants, until fifteen days' notice by certified mail shall be given the owner or
occupant to destroy such plants or a search warrant shall be issued on probable cause shown. In
all such instances, the county commission shall bear the cost of destruction and notification.

Section B. Section A of this act is hereby submitted to the qualified voters of this state
for approval or rejection at an election which is hereby ordered and which shall be held and
conducted on Tuesday next following the first Monday in November, 2011, pursuant to the laws
and constitutional provisions of this state for the submission of referendum measures by the
general assembly, and section A of this act shall become effective when approved by a majority
of the votes cast thereon at such election and not otherwise.